Vertex’s Latest Bid For Kalydeco Label Expansion Heads To FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Supplemental NDA for use in adult cystic fibrosis patients with R117H mutation is based on a pre-specified subgroup analysis of 50 patients from a 69-patient pivotal trial that failed its primary efficacy endpoint.